To include your compound in the COVID-19 Resource Center, submit it here.

Xifaxan rifaximin: Additional Phase III data

Additional data from the double-blind, international Phase III TARGET 3 trial in 636 patients with IBS-D showed that retreatment with thrice-daily 550 mg oral Xifaxan met the secondary composite endpoint of a greater proportion of responders based on both IBS-related abdominal pain and stool consistency during the first 6-week treatment phase and who continued to respond without recurrence through week 12 independent of any additional treatment vs. placebo (p=0.0419). A treatment phase comprised a 2-week

Read the full 759 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers